These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18844493)

  • 1. Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis.
    Husek P; Svagera Z; Vsianský F; Franeková J; Simek P
    Clin Chem Lab Med; 2008; 46(10):1391-7. PubMed ID: 18844493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and traditional biomarkers of bone turnover in postmenopausal women.
    Pohlídal A; Husek P; Palicka V; Slabík D; Hill M; Matucha P
    Clin Chem Lab Med; 2003 Jan; 41(1):74-8. PubMed ID: 12636053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies.
    Husek P; Pohlídal A; Slabík D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 767(1):169-74. PubMed ID: 11863289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of salt restriction on urine hydroxyproline excretion in postmenopausal women.
    Need AG; Morris HA; Cleghorn DB; De Nichilo D; Horowitz M; Nordin BE
    Arch Intern Med; 1991 Apr; 151(4):757-9. PubMed ID: 2012460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.
    Delmas PD; Schlemmer A; Gineyts E; Riis B; Christiansen C
    J Bone Miner Res; 1991 Jun; 6(6):639-44. PubMed ID: 1887826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary bone resorption markers in patients with metabolic bone disorders.
    Ohishi T; Kushida K; Takahashi M; Kawana K; Yagi K; Kawakami K; Horiuchi K; Inoue T
    Bone; 1994; 15(1):15-20. PubMed ID: 8024845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis.
    Eastell R; Colwell A; Hampton L; Reeve J
    J Bone Miner Res; 1997 Jan; 12(1):59-65. PubMed ID: 9240726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
    J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of hormone replacement therapy in bone resorption, in post-menopausal women].
    Villaseca P; Arteaga E; Campusano C; López JM; Rojas A; Nazar G; O'Brien A
    Rev Med Chil; 1996 Dec; 124(12):1439-46. PubMed ID: 9334477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps): correlation to hydroxyproline.
    Silsand T; Reine A; Dugal S; Lunde T; Smedsrud B; Seeberg T
    Scand J Clin Lab Invest; 1995 Apr; 55(2):187-92. PubMed ID: 7667612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis.
    Yilmaz N; Bayram M; Erbåğci AB; Kilinçer MS
    Clin Chem Lab Med; 1999 Feb; 37(2):137-43. PubMed ID: 10219502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease.
    Sarno M; Sarno L; Baylink D; Drinkwater B; Farley S; Kleerekoper M; Lang R; Lappe J; Licata A; McClung M; Miller P; Nattrass S; Recker R; Schwartz EN; Tucci JR; Wolf S; Powell H; Tjersland G; Warnick GR
    Clin Chem Lab Med; 2001 Mar; 39(3):223-8. PubMed ID: 11350019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of bone resorption by divided-dose calcium supplementation in early postmenopausal women.
    Scopacasa F; Need AG; Horowitz M; Wishart JM; Morris HA; Nordin BE
    Calcif Tissue Int; 2000 Dec; 67(6):440-2. PubMed ID: 11289691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.